Mayinglong Pharmaceutical Group (600993) Fair Value & Analysis
Healthcare · CN · Market cap 10.2B CNY
Analysis
Mayinglong Pharmaceutical Group (600993) currently trades at ¥22.85, while our model-based Fair Value estimate is ¥29.68 — implying the stock looks roughly 29.9% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers first and second category medical devices, household products, electronic products, daily necessities, hygiene products, and disinfection products, as well as automobile freight services. In addition, the company is involved in the retail and wholesale of medical devices and medicines; provision of hospital and medical management service; and hospital operations. Further, it imports raw and auxiliary materials, machinery and equipment, instruments and meters, spare parts and related technologies; and exports its products. Mayinglong Pharmaceutical Group Co., Ltd. was founded in 1582 and is …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.